Report Sections

See All Reports

  • HP:0007018: Attention deficit hyperactivity disorder
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0007018: Attention deficit hyperactivity disorder

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (9)


    Name (Synonyms) Correlation
    drug817 COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection Wiki 0.71
    drug4368 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki 0.50
    drug412 Atomoxetine hydrochloride Wiki 0.50
    Name (Synonyms) Correlation
    drug1821 Guanfacine hydrochloride (SPD503) Wiki 0.50
    drug819 COVID-19 antibodies testing Wiki 0.50
    drug2188 Interview by psychologists Wiki 0.50
    drug460 Azithromycin Tablets Wiki 0.35
    drug1970 Hydroxychloroquine Sulfate Wiki 0.14
    drug3195 Placebo Wiki 0.02

    Correlated MeSH Terms (24)


    Name (Synonyms) Correlation
    D001289 Attention Deficit Disorder with Hyperactivity NIH 1.00
    D006948 Hyperkinesis NIH 0.71
    D006929 Hyperaldosteronism NIH 0.50
    Name (Synonyms) Correlation
    D054559 Hyperphosphatemia NIH 0.50
    D004314 Down Syndrome NIH 0.50
    D007008 Hypokalemia NIH 0.50
    D008595 Menorrhagia NIH 0.50
    D000309 Adrenal Insufficiency NIH 0.50
    D001997 Bronchopulmonary Dysplasia NIH 0.35
    D014552 Urinary Tract Infections NIH 0.35
    D009080 Mucocutaneous Lymph Node Syndrome NIH 0.29
    D000067877 Autism Spectrum Disorder NIH 0.27
    D006470 Hemorrhage NIH 0.25
    D004194 Disease NIH 0.23
    D002659 Child Development Disorders, Pervasive NIH 0.20
    D001321 Autistic Disorder NIH 0.15
    D020141 Hemostatic Disorders NIH 0.13
    D001778 Blood Coagulation Disorders NIH 0.13
    D006973 Hypertension NIH 0.10
    D013577 Syndrome NIH 0.04
    D003141 Communicable Diseases NIH 0.03
    D007239 Infection NIH 0.02
    D045169 Severe Acute Respiratory Syndrome NIH 0.02
    D018352 Coronavirus Infections NIH 0.02

    Correlated HPO Terms (10)


    Name (Synonyms) Correlation
    HP:0002487 Hyperkinetic movements HPO 0.71
    HP:0002905 Hyperphosphatemia HPO 0.50
    HP:0000132 Menorrhagia HPO 0.50
    Name (Synonyms) Correlation
    HP:0002900 Hypokalemia HPO 0.50
    HP:0000846 Adrenal insufficiency HPO 0.50
    HP:0000859 Hyperaldosteronism HPO 0.50
    HP:0000729 Autistic behavior HPO 0.27
    HP:0000717 Autism HPO 0.15
    HP:0001928 Abnormality of coagulation HPO 0.13
    HP:0000822 Hypertension HPO 0.10

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder

    This interventional multicenter dose-optimization Phase IV PASS conducted in Europe and the USA evaluates the comparative long-term safety and efficacy of SPD503 in children and adolescents aged 6 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) for whom stimulants are not suitable, not tolerated, or shown to be ineffective. The study will be conducted in two parts: Study Part A (randomized, double-blinded, parallel-group, placebo- and active comparator-controlled, 3-treatment arm safety and efficacy evaluation of SPD503) and Study Part B (open label SPD503 treatment).

    NCT04085172
    Conditions
    1. Attention Deficit Hyperactivity Disorder (ADHD)
    Interventions
    1. Drug: Guanfacine hydrochloride (SPD503)
    2. Drug: Atomoxetine hydrochloride
    3. Other: Placebo
    MeSH:Hyperkinesis Attention Deficit Disorder with Hyperactivity
    HPO:Attention deficit hyperactivity disorder Hyperactivity Hyperkinetic movements

    Primary Outcomes

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 10 in both Part A and Part B of the study.

    Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 10

    Time: Baseline, Week 10

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 18 in Part A of the study.

    Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 18

    Time: Baseline, Week 18

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 49 in both Part A and Part B of the study.

    Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 49

    Time: Baseline, Week 49

    Secondary Outcomes

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. Cognitive domain, sustained attention will be measured by the CANTAB RVP task. RVP measures the ability to sustain attention over time and is a sensitive measure of frontal-parietal function. In this task, single digits appear in a pseudo--random order at a rate of 100 digits per minute in a box at the center of the screen. Participants are to detect a 3-digit target sequence (e.g. 2-4-6) and respond by pressing a button at the bottom of the screen when the final number of the sequence appears on the screen.

    Measure: Change from Baseline in the Rapid Visual Information Processing (RVP) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments, SWM is a component of cognitive executive function which is measured by SWM task of CANTAB between the errors. The ability to retain spatial information and manipulate remembered items in working memory will be measured with the SWM task of CANTAB which is self-ordered and assesses the individual's ability to strategize heuristically. The test is a sensitive measure of frontal lobe and executive dysfunction.

    Measure: Change from Baseline in the Spatial Working Memory (SWM) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments.Response control or inhibition cognitive domain will be measured by the CANTAB SST. SST measure response inhibition. The participant must respond to an arrow stimulus by touching either of 2 choices depending on the direction the arrow points. If an audio tone is present, the participant is not to respond.

    Measure: Change from Baseline in the Stop Signal Task (SST) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. Recognition memory of cognition domain will be measured by the CANTAB DMS task. DMS measures both simultaneous matching and short-term visual memory. The participant is shown a complex visual pattern (the sample) and after a brief delay, 4 similar patterns. The participant must identify the pattern that matches the sample.

    Measure: Change from Baseline in the Delayed Matching to Sample (DMS) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: Sexual maturation will be measured by Tanner stage. The stage of puberty or sexual maturation will be evaluated for each participant according to Tanner staging. The Tanner stage for genitals (male, stages I-V), breasts (females, stages I-V), and pubic hair (both sexes, stages I-V) will be documented at the specified times.

    Measure: Tanner Stage in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: Physical examinations will include height and weight. Growth will be measured by weight, height, and BMI. Body mass index is a measure of body fat based on height and weight. Vital signs will be assessed based on blood pressure, pulse rate, respiratory rate and body temperature in both Part A and Part B. The HR, PR interval, QRS interval, and QT interval will be measured from all ECGs and the QTcB and QTcF assessed at specified time points in both Part A and Part B of the study.

    Measure: Number of participants with clinically significant changes in Vital signs, ECG, Physical Examination

    Time: From start of study drug administration up to follow up (week 52)

    Description: Psychiatric symptoms will be measured by the Brief Psychiatric Rating Scale for Children (BPRS-C) total score. The 21 items of the clinician-rated BPRS-C are grouped into the following 7 scales: depression, anxiety, psychomotor excitation, behavior problems, withdrawal retardation, thinking disturbance, and organicity. Each item of the 21 items is clinician-graded using the following 7-point severity Likert-scale from 0 to 6 (not present=0; very mild=1; mild=2; moderate=3; moderately severe=4; severe=5; extremely severe=6. BPRS-C will be assessed at specified time points in both Part A and Part B.

    Measure: Brief Psychiatric Rating Scale for Children (BPRS-C)

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

    Description: The C-SSRS is a structured tool to assess suicidal ideation and behavior. A maximum of 19 items will be completed as follows: 7 items are required, a potential 10 additional items will be completed upon a positive response to a required item, and 2 items completed if suicide or suicide-like behavior is observed during the interview. The C-SSRS uses dichotomous scales (i e, yes or no), Likert scales, and text or narrative to further describe thoughts or behaviors. C-SSRS Score will be assessed at specified time points in both Part A and Part B.

    Measure: Columbia- Suicide Severity Rating Scale (CSSRS)

    Time: Baseline (from start of study drug administration) to Week 52

    Description: UKU rating scale was developed for clinicians to assess side effects of psychopharmacological medications based on interviews and other relevant source information. UKU items relevant to the established safety profile of SPD503 such as Increased Duration of Sleep, Asthenia or Lassitude or lncreased Fatigability, Sleepiness or Sedation, and Orthostatic Dizziness. UKU rating scale will be assessed at specified time points in both Part A and Part B.

    Measure: Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36, Week 49, Week 50, Week 51 and Week 52 Part B: Baseline, Week 10, Week 23, Week 36, Week 49, Week 50, Week 51 and Week 52

    Description: Sedative effects will be measured by participant ratings on the Pediatric Daytime Sleepiness Scale (PDSS). The PDSS is a self-reported assessment of daytime sleepiness in children aged 11 to 15 years. PDSS questionnaire was designed to be easy to administer, score, and interpret. Sleepiness-related questions are based on previous research of situations that can be sensitive to sleep loss in this age group. The 8 questions are scored on Likert-scale from 0 to 4 (never=0; seldom=1; sometimes=2; frequently=3; always=4). The total score on the PDSS can range from 0 (never sleepy) to 32 (always sleepy). PDSS will be assessed at specified time points in both Part A and Part B.

    Measure: Pediatric Daytime Sleepiness Scale (PDSS)

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

    Description: The ADHD-RS-5 (DuPaul et al., 2016) is used widely by mental health, educational, and medical practitioners in screening, diagnosis, and treatment evaluation to determine the frequency and severity of ADHD symptoms and impairments in children and adolescents. Attention-deficit/hyperactivity disorder symptoms is measured by the investigator-administered ADHD Rating Scale-5 (ADHD-RS-5) total score and hyperactivity/impulsivity and inattentiveness symptoms as subscale scores. The ADHD-RS-5 is based on the diagnostic criteria for ADHD as described in the DSM-5 and consists of 2 symptom subscales, inattention and hyperactivity-impulsivity, each with 9 items and a total scale of 18 items. Each item in the subscale is scored with a value ranging from 0 (no symptoms) to 3 (severe symptoms). The total score can range from 0 to 54. ADHD-RS-5 Total Score and Subscales wiil be assessed at specified time points in both Part A and Part B.

    Measure: ADHD Rating Scale-5 (ADHD-RS-5) Total Score and Subscales

    Time: Part A: Baseline, Week 1, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

    Description: Global clinical measurement of ADHD improvement as measured by Clinical Global Impression-Improvement (CGI-I) using the Clinical Global Impression-Severity (CGI-S) to establish baseline. The CGI scale will be used to evaluate the severity of mental illness over time. The CGI-S will be administered to assess the severity of mental illness at baseline. The CGI-S is scored on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). The CGI-I is also scored on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). CGI-I will be measured at specified time points in both Part A and Part B.

    Measure: Clinical Global Impression-Improvement (CGI-I)

    Time: Part A: Week 1, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Week 10, Week 23, Week 36 and Week 49

    Description: The Parent Report Form of the Child Health and Illness Profile - Child Edition (CHIP-CE:PRF) will be administered to provide information on self-esteem and school functioning in pediatric participants diagnosed with ADHD. The 5 domains and 12 subdomains covered in the 76 items comprising the CHIP-CE:PRF. Satisfaction: with health (7 items) and self (4 items); Comfort: physical (9 items) and emotional symptoms (9 items) and activity restrictions (4 items) due to illness; Resilience: behaviors and family involvement (8 items) in activities likely to enhance health, Social problem-solving (5 items),Physical activity (6 items); Risk avoidance: behaviors that if not avoided are likely to pose risks to health: Individual risk avoidance (4 items), Threats to achievement (10 items); Achievement: developmentally appropriate role functioning in school and with peers: Academic performance (5 items), Peer relations (5 items). CHIP-CE: PRF will be assessed in both Part A and Part B.

    Measure: Child Health and Illness Profile - Child Edition: Parent Report Form (CHIP-CE:PRF)

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

    Description: School performance will be measured by teacher ratings of academic skills using the APRS at specified time points in both Part A and Part B. The APRS is a reliable rating scale that has been shown to be valid in assessing teacher perceptions of the quality of a student's academic competency. The scale includes 19 items that are directed toward work performance in various participant areas; academic success, behavioral control in academic situations, and attention to assignments. Teachers mark responses in a Likert-scale format from 1 (never or poor) to 5 (very often or excellent). From the APRS, a total score and the following 3 subscale scores are calculated: academic success, impulse control, and academic productivity.

    Measure: Academic Performance Rating Scale (APRS)

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49
    2 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

    NCT04278404
    Conditions
    1. Coronavirus Infection (COVID-19)
    2. Pulmonary Arterial Hypertension
    3. Urinary Tract Infections in Children
    4. Hypertension
    5. Pain
    6. Hyperphosphatemia
    7. Primary Hyperaldosteronism
    8. Edema
    9. Hypokalemia
    10. Heart Failure
    11. Hemophilia
    12. Menorrhagia
    13. Insomnia
    14. Pneumonia
    15. Skin Infection
    16. Arrythmia
    17. Asthma in Children
    18. Bronchopulmonary Dysplasia
    19. Adrenal Insufficiency
    20. Fibrinolysis; Hemorrhage
    21. Attention Deficit Hyperactivity Disorder
    22. Multisystem Inflammatory Syndrome in Children (MIS-C)
    23. Kawasaki Disease
    24. Coagulation Disorder
    25. Down Syndrome
    Interventions
    1. Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Down Syndrome Menorrhagia Hypertension Hemostatic Disorders Mucocutaneous Lymph Node Syndrome Blood Coagulation Disorders Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Disease Syndrome Hemorrhage Attention Deficit Disorder with Hyperactivity
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Adrenal insufficiency Attention deficit hyperactivity disorder Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism

    Primary Outcomes

    Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Elimination rate constant (ke) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Half-life (t1/2) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Absorption rate constant (ka) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: AUC (area under the curve) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Maximum concentration (Cmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
    3 Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak

    In response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).

    NCT04416360
    Conditions
    1. Autism Spectrum Disorder
    2. Attention-deficit Hyperactivity Disorder
    Interventions
    1. Other: Interview by psychologists
    MeSH:Hyperkinesis Disease Autistic Disorder Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Attention deficit hyperactivity disorder Autism Autistic behavior Hyperactivity Hyperkinetic movements

    Primary Outcomes

    Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.

    Measure: Interview of the parents : contextual data

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 1 month

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 3 months

    Description: Data relating to disease and management of care. Experience of the referring caregiver.

    Measure: Interview of the referring caregiver : data relating to disease and management of care

    Time: 3 months
    4 Brain Imaging and Infant Development

    The aims of the BIBS Study The Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby's brain develops from before birth, up until 3-4 years of age. Working with children from a variety of backgrounds and communities, the investigators use a combination of state-of-the-art diagnostic tools such as MRI scans alongside traditional behavioural assessments to capture the earliest information on infant brain development. The focus of the BIBS study MRI scanning is a safe way of producing detailed images using strong magnetic fields and radio waves. It does not use X-ray. Along with learning more about brain development in general, the investigators also try to identify features that may in future help predict whether a child will or will not develop traits of conditions such as Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this may help target useful interventions early on, helping children who are most in need. Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have been given ethical approval to include testing for this infection in the mothers and children participating in the study. This may provide an opportunity to better understand how mother and baby respond to infections. The investigators particularly welcome mothers who have had a positive COVID-19 test during their pregnancy to join the study.

    NCT04443179
    Conditions
    1. Autism Spectrum Disorder
    2. Attention Deficit Hyperactivity Disorder
    3. Neurodevelopmental Conditions
    4. COVID-19
    MeSH:Disease Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder
    HPO:Attention deficit hyperactivity disorder Autistic behavior

    Primary Outcomes

    Measure: Neurodevelopmental Outcomes

    Time: 3-4 years of age

    HPO Nodes


    HP:0007018: Attention deficit hyperactivity disorder
    Genes 387
    TGIF1 SH2B1 EEF1A2 GNE TBL1X ALG13 HSPG2 NODAL GNE POLA1 AGTR2 ZNF711 GTF2IRD1 SLC9A7 NECAP1 PHF21A FRMPD4 CNKSR2 SATB2 KIF11 SHH GABRG2 ARVCF SLITRK1 SETD5 MED13 YY1 RREB1 GNB5 TRAPPC14 STXBP1 ARX AARS1 PIEZO2 FGF8 DMD RAB39B GAS1 TGFBR2 FOXH1 CLIP2 ELN GRIN2A FANCD2 MYT1L HIRA GP1BB SVBP ACTL6B ADNP DLL1 SEC24C SIX3 CDK8 TIMM8A GABRG2 ELN PIK3CA HCN1 PAH CLTC SATB2 TLK2 WAC PMS2 FOXH1 CLCN4 GABRA5 GABRG2 CDON TSC1 GDI1 SLC1A2 PTCHD1 GAS1 HDC GABRB2 NPAP1 KRAS JRK NTRK2 CDON CDK19 KMT2E IGF2 SHH DISP1 ASPM TANC2 STS ZIC2 ACTL6B SNORD115-1 LIG4 GALC MADD NF1 DISP1 FGD1 KCNB1 MKRN3-AS1 FOXH1 TSPAN7 YWHAG SEMA3E TDGF1 IKBKG DHTKD1 FAN1 TKT FTSJ1 MED13 GLI2 FGF8 ABCD1 YWHAG PPM1D CNKSR2 GRIA4 FGFR1 IGF1 ZNF81 TAF1 KMT2A PWRN1 IPW HOXA2 CHRNA7 FLI1 PAK3 SNRPN DISP1 DALRD3 TRIO STAG2 ARID2 KCNA2 SIX3 RAI1 SH2B1 MED12 NKAP MSH6 ZIC2 WDFY3 KIF14 CACNA1H GABRA2 MSH2 DHCR7 FGF8 SHH SYNGAP1 DYM RIC1 NOP56 FGFR3 NODAL AP3B2 DDX6 PTCH1 ZIC2 RAD21 NUS1 SOX5 KANSL1 DLL1 RERE SLC6A8 FGF12 DNM1 ODC1 KAT8 BCORL1 MAGEL2 ACSL4 PCNT TET3 STS CLTC CDON SPRED1 MID2 CDKN1C STAG2 PPP1R12A SLC13A5 FBXW11 PTCH1 GLI2 ANAPC1 PWAR1 WAC SCN8A SLC2A1 THRB CNKSR2 TSC2 GLUD1 MAPK1 CARS1 IFNG NIPBL USP9X MKRN3 PANK2 FGFR1 DLL1 NSUN2 RAI1 TCF20 OPHN1 PCGF2 DYRK1A RPS20 FMR1 MED12 CSGALNACT1 IL1RAPL1 APC2 ODC1 CACNA1A TBX1 NSD1 JMJD1C C12ORF4 TBX1 EPCAM MECP2 TBL2 SIM1 TBX1 WWOX SYNJ1 METTL5 DNAJC12 PRNP TUBB2B CSNK2A1 FOXP1 RFC2 TMCO1 GATA4 SNORD116-1 LIMK1 MED12 MYT1L CRBN SIX3 PTCHD1 ATP6V1A GLI2 SMPD1 ARV1 CRKL PMS1 SZT2 MCTP2 BPTF SIN3A SYP CDON ZMIZ1 TBX1 ZNF41 STEEP1 IQSEC2 CACNA1B CIC GABRB3 ACTL6A DEAF1 ZIC2 PSMD12 SCN8A MLH1 GABRA1 FOXH1 USP27X FGD1 TSC2 PHIP GRIN2D FGF8 SNRPN NDP NBN PRKCG TANC2 TGIF1 NLGN1 WAC UBE3A ZMIZ1 SMC1A HDAC4 TDGF1 TSC1 HMGA2 PTCH1 IQSEC1 GLI2 SEMA4A GAS1 PPP3CA GAS1 DOCK3 UFD1 TGIF1 SH3KBP1 PLAG1 GTF2I KDM3B GNAQ CYFIP2 KCNA2 KANSL1 GRIN2A PTCH1 NR2F1 TRAK1 UBA5 SETD5 TDGF1 RAI1 MED12L PARS2 TGIF1 BMPR1A CHD7 ARF1 UPF3B ALKBH8 SMC1A CDH2 NDN SETD2 UPF3B OCRL DHDDS HCFC1 SMC3 TDGF1 ZDHHC9 DLL1 TRMT1 SHH DPH1 SIX3 RERE TKT HDAC8 MLH3 HERC2 SRPX2 STAG2 DLG3 DRD5 MLXIPL MAP1B IQSEC2 BCR RSRC1 SETBP1 SPG7 SCN3A LHCGR BCORL1 NODAL BAZ1B DLL1 TRAPPC4 MED12 COMT USP7 DRD4 FLII NTNG1 ARHGEF6 DYNC1I2 NODAL RPS6KA3 AUTS2 RLIM TRIO PAH DISP1
    Protein Mutations 2
    D203E G143E

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0007018: Attention deficit hyperactivity disorder
    Genes 387
    TGIF1 SH2B1 EEF1A2 GNE TBL1X ALG13 HSPG2 NODAL GNE POLA1 AGTR2 ZNF711 GTF2IRD1 SLC9A7 NECAP1 PHF21A FRMPD4 CNKSR2 SATB2 KIF11 SHH GABRG2 ARVCF SLITRK1 SETD5 MED13 YY1 RREB1 GNB5 TRAPPC14 STXBP1 ARX AARS1 PIEZO2 FGF8 DMD RAB39B GAS1 TGFBR2 FOXH1 CLIP2 ELN GRIN2A FANCD2 MYT1L HIRA GP1BB SVBP ACTL6B ADNP DLL1 SEC24C SIX3 CDK8 TIMM8A GABRG2 ELN PIK3CA HCN1 PAH CLTC SATB2 TLK2 WAC PMS2 FOXH1 CLCN4 GABRA5 GABRG2 CDON TSC1 GDI1 SLC1A2 PTCHD1 GAS1 HDC GABRB2 NPAP1 KRAS JRK NTRK2 CDON CDK19 KMT2E IGF2 SHH DISP1 ASPM TANC2 STS ZIC2 ACTL6B SNORD115-1 LIG4 GALC MADD NF1 DISP1 FGD1 KCNB1 MKRN3-AS1 FOXH1 TSPAN7 YWHAG SEMA3E TDGF1 IKBKG DHTKD1 FAN1 TKT FTSJ1 MED13 GLI2 FGF8 ABCD1 YWHAG PPM1D CNKSR2 GRIA4 FGFR1 IGF1 ZNF81 TAF1 KMT2A PWRN1 IPW HOXA2 CHRNA7 FLI1 PAK3 SNRPN DISP1 DALRD3 TRIO STAG2 ARID2 KCNA2 SIX3 RAI1 SH2B1 MED12 NKAP MSH6 ZIC2 WDFY3 KIF14 CACNA1H GABRA2 MSH2 DHCR7 FGF8 SHH SYNGAP1 DYM RIC1 NOP56 FGFR3 NODAL AP3B2 DDX6 PTCH1 ZIC2 RAD21 NUS1 SOX5 KANSL1 DLL1 RERE SLC6A8 FGF12 DNM1 ODC1 KAT8 BCORL1 MAGEL2 ACSL4 PCNT TET3 STS CLTC CDON SPRED1 MID2 CDKN1C STAG2 PPP1R12A SLC13A5 FBXW11 PTCH1 GLI2 ANAPC1 PWAR1 WAC SCN8A SLC2A1 THRB CNKSR2 TSC2 GLUD1 MAPK1 CARS1 IFNG NIPBL USP9X MKRN3 PANK2 FGFR1 DLL1 NSUN2 RAI1 TCF20 OPHN1 PCGF2 DYRK1A RPS20 FMR1 MED12 CSGALNACT1 IL1RAPL1 APC2 ODC1 CACNA1A TBX1 NSD1 JMJD1C C12ORF4 TBX1 EPCAM MECP2 TBL2 SIM1 TBX1 WWOX SYNJ1 METTL5 DNAJC12 PRNP TUBB2B CSNK2A1 FOXP1 RFC2 TMCO1 GATA4 SNORD116-1 LIMK1 MED12 MYT1L CRBN SIX3 PTCHD1 ATP6V1A GLI2 SMPD1 ARV1 CRKL PMS1 SZT2 MCTP2 BPTF SIN3A SYP CDON ZMIZ1 TBX1 ZNF41 STEEP1 IQSEC2 CACNA1B CIC GABRB3 ACTL6A DEAF1 ZIC2 PSMD12 SCN8A MLH1 GABRA1 FOXH1 USP27X FGD1 TSC2 PHIP GRIN2D FGF8 SNRPN NDP NBN PRKCG TANC2 TGIF1 NLGN1 WAC UBE3A ZMIZ1 SMC1A HDAC4 TDGF1 TSC1 HMGA2 PTCH1 IQSEC1 GLI2 SEMA4A GAS1 PPP3CA GAS1 DOCK3 UFD1 TGIF1 SH3KBP1 PLAG1 GTF2I KDM3B GNAQ CYFIP2 KCNA2 KANSL1 GRIN2A PTCH1 NR2F1 TRAK1 UBA5 SETD5 TDGF1 RAI1 MED12L PARS2 TGIF1 BMPR1A CHD7 ARF1 UPF3B ALKBH8 SMC1A CDH2 NDN SETD2 UPF3B OCRL DHDDS HCFC1 SMC3 TDGF1 ZDHHC9 DLL1 TRMT1 SHH DPH1 SIX3 RERE TKT HDAC8 MLH3 HERC2 SRPX2 STAG2 DLG3 DRD5 MLXIPL MAP1B IQSEC2 BCR RSRC1 SETBP1 SPG7 SCN3A LHCGR BCORL1 NODAL BAZ1B DLL1 TRAPPC4 MED12 COMT USP7 DRD4 FLII NTNG1 ARHGEF6 DYNC1I2 NODAL RPS6KA3 AUTS2 RLIM TRIO PAH DISP1
    Protein Mutations 2
    D203E G143E

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook